Help us determine the safety and efficacy of an experimental drug
Closed for Enrollment
Study Name
Biogen SOD1 Phase III Clinical Trial
PI
Michael Benatar, MD, PhD
Study Type
Interventional (Clinical Trial), Phase III, Randomized, Placebo-controlled
Eligible Population
Individuals affected with ALS, and positive for an SOD1 gene mutation that is associated with rapidly progressive disease
Study Purpose/Goals
To determine the safety and efficacy of the experimental drug BIIB067 in patients with SOD1 ALS
Procedures/Participation
40 weeks of participation
- Screening: up to 4 weeks
- Treatment: 32 weeks (9 doses, once every 2 weeks x 2 doses, then once every 4 weeks)
- Follow-up: 4 weeks
- Open label extension
Procedures
- Medical history and medication review
- Drug dosing
- Blood, urine and CSF collection
- Neurological exam
- Muscle testing
- Electrocardiogram
- Physical exam
- Surveys
- Breathing tests
- Biomarker procedures (HHD, MUNIX)
Contact
Join our family - together, we can change the course of this disease.
Join our family
Together, we can change the course of this disease.
ALS Treatment
About Us
Copyright © 2020. ALS Center at the University of Miami. All Rights Reserved. Branding by Mok2